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Summary The effect of verapamil on hepatocarcinogenesis induced by N-nitrosomorpholine (NNM) was
investigated in male Sprague-Dawley rats. Rats were given drinking water containing NNM for 8 weeks and
received i.p. injections of verapamil or vehicle every other day for 16 weeks from the start of the experiment.
Pre-neoplastic and neoplastic lesions staining positive for y-glutamyl transpeptidase (GGT) or the placental
type of glutathione-S-transferase (GST-P) were examined histochemically at week 16. Prolonged administra-
tion of verapamil resulted in a significant decrease in the number ofGGT-positive and GST-P-positive lesions.
The incidence and volume as a percentage of parenchyma of hepatocellular carcinomas were also significantly
less in rats treated with verapamil than in controls. Administration of verapamil significantly decreased the
labelling indices of pre-neoplastic lesions and adjacent liver. These findings indicate that verapamil inhibits
hepatocarcinogenesis and that this may be related to its inhibitory effect on cell proliferation in neoplastic
lesions and surrounding hepatocytes.
Liver regeneration is characterised by coordinated waves of
DNA synthesis that cease when the hepatocyte number has
been restored to normal. This complex response is regulated
by many circulating substances, including serum factors
(Michalopoulos et al., 1984), epidermal growth factor
(Bucher et al., 1978), insulin (Bucher et al., 1981) and cor-
ticosteroids (Isohashi et al., 1979).
A role ofcalcium in the course ofhepatocyte proliferation
has been suggested by many investigators. Calcium channel
blockers can inhibit hepatocyte proliferation by decreasing
their cytosolic calcium concentration (Baserga & Surmacz,
1987; Eckl et al., 1987; Nakata et al., 1987). They also affect
hepatocyte proliferation by attenuating the al-adrenergic
action (Reinhart et al., 1984; Exton, 1985; Tsukamoto &
Kojo, 1987). Moreover, administration of calcium channel
blockers significantly suppressed the activities of hepatic
thymidylate synthetase and thymidine kinase after partial
hepatectomy of rats (Tsukamoto & Kojo, 1987). Verapamil
inhibited hepatocyte DNA synthesis and c-myc expression
induced by epidermal growth factor and prostaglandins
(Skouteris & Kaser, 1991). These findings suggest that a
calcium channel blocker may affect hepatocarcinogenesis.
Therefore, in the present study, we examined the effect of
verapamil on the development of enzyme-altered hepatic
lesions by treating rats with verapamil from the start of oral
administration of a carcinogen.
Materials and methods
Animals
Forty young male Sprague-Dawley rats, initially weighing
80-100 g, were purchased from SLC (Shizuoka, Japan). The
animals were housed in suspended, wire-bottomed metal
cages in animal quarters with controlled temperature
(21-22°C), humidity (30-50%), and lighting (12 h darkness/
12h light), and given free access to regular chow pellets
(Oriental Yeast, Tokyo, Japan).
Experimental design
Animals were randomly divided into two groups of 20 rats
and each was treated as follows: Group 1 was given drinking
water containing 175 mg/liter of NNM (Signa, St. Louis,
MO, USA) for 8 weeks. From the beginning of the experi-
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ment, rats also received i.p. injections of the vehicle, 0.9%
NaCl solution, every other day until the end of the experi-
ment in week 16. NNM was dissolved in distilled water at
35g/liter, stored in a cool place. This stock solution was
diluted to 175 mg/liter with tap water just before use,
renewed every other day, and supplied to the rats ad libitum
from bottles. From week 9 until the end of the experiment,
rats were given normal tap water only. Group 2 was also
given NNM for 8 weeks in the same way as Group 1 and
received i.p. injections of verapamil (Sigma) dissolved in
0.9% NaCl solution every other day at a dose of 20 mg/kg
body weight from the start of the experiment. Injections were
given every other day in a volume of 1 ml, between 2 and
3 p.m.
Histological andhistochemical studies
In week 16, all surviving rats (not starved) were killed by
ether anesthesia. The liver was promptly excised and sections
of 2-3 mm thickness obtained from the left and middle lobes
were fixed in cold acetone (0-4°C) for 6 h, and embedded in
paraffin. Serial sections of 31Am thickness were stained with
hematoxylin and eosin, for examination of GGT activity as
decribed by Ruttenberg et al. (1969), and for examination of
GST-P by an immunohistochemical PAP method (Stern-
berger et al., 1970) using anti-rat GST-P rabbit serum (Bio
Prep Medlabs, Dublin, Ireland).
Volumetric analysis
Serial sections were scored for GGT-positive lesions and
GST-P positive lesions without knowledge of their group of
origin. Only pre-neoplastic or neoplastic lesions of 0.2 mm or
more in longest diameter in the plane of section were
counted, because reproducible evaluation of lesions of less
than 0.2 mm in diameter was impossible. The transectional
area of the lesions in the plane of the tissue section and the
area of the entire liver section were measured with a LA-500
Personal Image Analyzer System (Pias, Tokyo, Japan). From
the measured area of transected lesions, the number of
lesions per unit volume was estimated by the method of Pugh
et al. (1983), and the mean volume of the lesions per unit
liver volume was calculated by the method of Campbell et al.
(1982).
Labelling indices ofenzyme-altered lesions andsurrounding
liver
The labelling indices of the enzyme-altered lesions and the
surrounding liver were examined at week 16. The labelling
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index was measured with an immunohistochemical analysis
kit (Becton-Dickinson, Mountain View, CA, USA) for assay-
ing BrdU incorporation (Gratzner, 1982; Morstyn et al.,
1983). For this purpose, five unstarved rats in each group
received an i.p. injection of 20 mgkg-' of BrdU, and 1 h
later they were killed with ether. Sections obtained from the
left liver lobe were immediately mounted on brass chucks
using OTC compound, frozen in dry ice-acetone (- 80°C),
and stored at - 70°C. Serial cryostat sections of 6tLm thick-
ness obtained from the frozen slices were fixed in 70%
ethanol (0-4°C) for 10 min. These sections were washed and
immersed in 2 N HCI solution for 30 min at room tem-
perature and then in 0.1 M Na2B407 to neutralise the acid.
They were then stained with anti-BrdU monoclonal antibody
(diluted 1:25) for 2 h at room temperature, washed, stained
with biotin-conjugated horse anti-mouse antibody (diluted
1:200) for 30 min, and stained with avidin-biotin-peroxidase
complex for 30 min. The reaction product was located with
3,3'-diaminobenzidine tetrahydrochloride. Cells containing
BrdU were identified by the presence of dark pigment over
their nuclei. For determining the labelling index, we counted
the number of BrdU-labelled cells among 500 cells in the
surrounding liver and in enzyme-altered lesions of 0.7-
1.2 mm longest diameter. The labelling index was expressed
as the percentage of labelled cells among the cells examined.
Statistical analysis
Results were analysed by the Chi-square test (Seigel, 1956) or
Student's t-test (Snedecor & Cochran, 1967). Data are shown
as means ± s.e. 'Significant' indicates a calculated P value of
less than 0.05.
Results
Body and liver weights
The body and liver weights of the NNM-treated rats are
summarised in Table I. At week 16, the rats treated with
verapamil had significantly lower body weights and liver
weights than controls.
Table I Body and liver weights of NNM-treated and control rats
Effective Liver
Group Body weight (g) number weight
number Treatmenta Initial Week 16 ofrats (g)
1 0.9% NaCl 90 2 388 5 20 15.7 0.5
2 Verapamil 91 ± 2 349± 6c 20 14.3 0.5b
aTreatments: 0.9% NaCI; NNM wasgiven orally for 8 weeks and i.p.
injections of0.9% NaCl were given every other day until the end ofthe
experiment; Verapamil; NNM was given orally for 8 weeks and i.p.
injections of20 mgkg-' ofverapamil were given every other day until
the end of the experiment. b'cSignificantly different from the value for
Group 1: bp<0.05 and "P<0.01.
Number, size and volume ofenzyme-altered lesions in the liver
Table II summarises the numbers, sizes, and volumes of
GST-P-positive lesions and GGT-positive lesions in NNM-
treated rats. Two dimensional data showed that GST-P
positive lesions and GGT-positive lesions were significantly
fewer in Group 2 (verapamil) than in Group 1 (0.9% NaCl).
The mean area of GGT-positive lesions was significantly
smaller in Group 2 than in Group 1. Statistical analysis of
the calculated volumetric data showed that the number and
volume as a percentage of parenchyma of GST-P-positive
lesions were both significantly less in Group 2 than in Group
1. The mean volume and the volume as a percentage of
parenchyma of GGT-positive lesions were also both
significantly less in Group 2 than in Group 1.
Incidences, numbers, sizes and volumes ofhepatocellular
carcinomas
Table III summarises the incidences of hepatocellular car-
cinomas and the numbers, sizes and volumes of hepatocel-
lular carcinomas in the tumour-bearing rats. Hepatocellular
carcinomas were found in 10 (50%) of the 20 untreated rats
examined. The incidences of hepatocellular carcinomas were
significantly less in Group 2 (verapamil) than in Group 1
(0.9% NaCl). Two dimensional data showed that the number
and the mean area of hepatocellular carcinomas were both
less in Group 2 than in Group 1, though the differences were
not significant. Statistical analysis of the volumetric data
showed lower values in Group 2 than in Group 1 for the
number of lesions per cm3 and the mean volume, and a
significantly lower value for the volume as a percentage of
the parenchyma of hepatocellular carcinomas.
Labelling indices ofenzyme-altered lesions andsurrounding
normal liver
Table IV summarises data on the labelling indices of pre-
neoplastic lesions and surrounding normal liver of NNM-
TableIII Numbers, sizesandvolumesofhepatocellularcarcinomasin
tumour-bearing rats
Group number 1 2
Treatmenta 0.9% NaCl Verapamil
Effective number of rats 20 20




No./cm2 3.88 ± 1.12 2.03 ± 0.59
Mean area (mm2) 4.44 ± 2.37 1.12 ± 0.50
Calculated volumetric
data on lesions
No./cm3 15.5 ± 3.5 13.7 ± 6.7
Mean volume (mm3) 2.92 ± 2.30 0.24 ± 0.15
Volume as % of parenchyma 8.96 ± 3.05 1.97 ± 0.73b
aFor explanation of treatments, see Table I. bSignificantly different
from the value for Group 1 at P<0.05.
Table II Numbers, sizes and volumes ofGST-P-positive lesions and GGT-positive lesions in
the liver of NNM-treated and control rats
Enzyme-altered lesions GST-P-positive lesions GGT-positive lesions
Group number 1 2 1 2
Treatmenta 0.9% NaCI Verapamil 0.9% NaCI Verapamil
Observed transectional
data on lesions
No./cm2 37.0 ± 3.4 16.4 ± 4.0c 2.9 ± 0.8 1.2 ± 0.4b
Mean area (mm2) 1.05 ± 0.13 0.97 ± 0.12 1.08 ± 0.29 0.40 ± 0.17b
Calculated volumetric
data on lesions
No./cm3 254 ± 24 107 ± 28c 13.2 ± 3.8 9.8 ± 3.5
Mean volume (mm3) 1.69 ± 0.32 1.69 ± 0.28 2.91 ± 0.99 0.57 0.15b
Volume as % of parenchyma 40.3 5.8 16.2 ± 3.5c 5.7 1.7 1.1 ±0.4b
aForexplanation oftreatments, seeTableI.b,cSignificantly different from thevalue forGroup
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Table IV Labelling indices of enzyme-altered lesions and adjacent
normal liver at week 16
Labelling index (%)
Group Enzyme-altered Adjacent
number Treatment' lesions liver
1 0.9% NaCl 2.82 ± 0.51 0.95 ± 0.17
2 Verapamil 1.57 ± 0.09b 0.35 ± 0.12b
aFor explanation of treatments, see Table I. bSignificantly different
from the value for Group 1 at P<0.05.
treated rats. The labelling indices of pre-neoplastic lesions
and adjacent liver were significantly lower in Group 2 than in
Group 1.
Discussion
In the present study, we found that prolonged administration
of verapamil from the start of treatment with a carcinogen
resulted in significant decreases in the number and the
volume as a percentage of the parenchyma of GST-P-positive
and GGT-positive hepatic lesions and the volume as a
percentage of the parenchyma of hepatocellular carcinomas.
The exact mechanism(s) involved in this effect ofverapamil is
unknown, but at least two possible explanations can be
considered.
The first possibility is an effect of calorific intake. Reduc-
tion of total calorific intake is considered to inhibit the
promotion of mammary tumours induced by 7,12-dimethyl-
benzanthracene and colon tumours induced by 1,2-dimethyl-
hydrazine (Klurfeld et al., 1987). Total calorific intake was
an important determinant of tumorigenesis in the mammary
gland and skin of mice, and body weight may be a more
sensitive indicator for this effect than calorific intake alone
(Albanes, 1987). In the present work, we found that rats
treated with verapamil had significantly lower body weights
than untreated rats at week 16.
A second possibility is inhibition of hepatocyte prolifera-
tion by decreasing their cytosolic calcium concentration.
Prolonged hypocalcemic conditions induced by parathyroid-
ectomy result in significant inhibition of the activity of
thymidylate synthetase and thymidine kinase with con-
comitant decrease of the DNA content in regenerating liver
(Nakata et al., 1987). Calcium channel blockers (verapamil,
diltiazem and nifedipine) decrease thymidylate synthetase and
thymidine kinase activities and reduce DNA content after
partial hepatectomy of rats (Tsukamoto & Kojo, 1987).
Moreover, verapamil was found to cause significant decrease
in the c-myc RNA level and DNA synthesis in cultured
hepatocytes treated with epidermal growth factor and prosta-
glandin suggesting that calcium is required during the pre-
synthetic period of hepatocyte proliferation (Skouteris &
Kaser, 1991). Mobilisation of calcium from intracellular
stores is also considered to be an important event in the
mitogenic response of hepatocyte to growth factors (Eckl et
al., 1987; Baserga & Surmacz, 1987). Calcium channel
blockers can cross the plasma membrane and modify the
intracellular calcium level by acting on organelle membranes.
All classes of calcium channel blockers have been shown to
inhibit release of calcium from mitochondria (Buss et al.,
1988). These findings suggest that verapamil inhibits
hepatocyte proliferation by decreasing their cytosolic calcium
level and that it also inhibits proliferation of enzyme altered
lesions and hepatocellular carcinomas induced by NNM.
Calcium channel blockers may also affect hepatocyte pro-
liferation by attenuating the a,-adrenergic action, because
al-receptors utilise calcium ion as an intracellular messenger
and need extracellular calcium ion to maintain physiological
responses (Reinhart et al., 1984; Exton, 1985; Tsukamoto &
Kojo, 1987). Moreover, calcium channel blockers have the
potential to antagonise non-calcium channel receptor sites on
the plasma membrane. Verapamil, diltiazem and nifedipine
have been shown to act as a-adrenergic antagonists in
various tissues (Godfraind et al., 1986). The xl-adrenergic
receptor stimulates DNA synthesis in primary serum-free
cultures of adult hepatocytes and in regenerating rat liver
after two-thirds partial hepatectomy (Cruise et al., 1988).
Norepinephrine stimulates incorporation of 3H thymidine in
primary cultures of adult rat hepatocytes in serum-free
medium containing epidermal growth factor and insulin. This
stimulation of DNA synthesis by norepinephrine was
strongly antagonised by the xl-adrenergic antagonist pra-
zocin, but not by an M2-antagonist nor by a P-adrenergic
blocker (Cruise et al., 1985). al-Adrenergic blockade, which
affects both epidermal growth factor receptor binding and
subsequent DNA synthesis in primary cultures of hepato-
cytes, can also modulate these processes during liver
regeneration after partial hepatectomy (Cruise et al., 1987).
Therefore, verapamil inhibits hepatocyte proliferation by
antagonising a,-adrenoceptors and may inhibit proliferation
of enzyme altered lesions and hepatocellular carcinomas
induced by NNM by antagonising oa,-adrenoceptors.
In the present work, we found that verapamil administra-
tion significantly reduced the labelling indices of pre-
neoplastic and neoplastic lesions and surrounding liver of
rats. We believe therefore that verapamil inhibit hepatocar-
cinogenesis by decreasing hepatocyte proliferation.
Abbreviations: GGT, y-glutamyl transpeptidase; GST-P, placental
type of glutathione-S-transferase; BrdU, bromodeoxyuridine; vera-
pamil, (±)-verapamil hydrochloride; NNM, N-nitrosomorpholine.
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